VLP-based monovalent ebola vaccines and methods of making and using same
US12427190B2 · kind B2 · utility
0Cited by
4References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 28, 2018 |
| Grant date | Sep 30, 2025 |
| Priority date | — |
| Expiry date | Aug 30, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/14134
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are virus-like particle (VLP)-based monovalent vaccine compositions. The compositions may comprise a spherical retroviral Group-specific Antigen (“Gag”) protein core and a single Ebola glycoprotein selected from either a Zaire (EBOV) glycoprotein or a Sudan (SUDV) glycoprotein. The Ebola glycoprotein may be incorporated into the surface of the spherical Gag core, wherein said VLP-based vaccine presents a single Ebola glycoprotein antigen.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.